We randomly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of body weight daily and 122 to receive initial ...

Cefonicid is a new second-generation cephalosporin that has broad-spectrum antibacterial activity, achieves high peak serum concentrations, and has a long half-life. The high serum concentration and ...

Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centers First study results expected in mid-2024 Endocarditis is an ...

Staphylococcus aureus bacteremia and endocarditis are serious infections that demand prompt clinical attention to ensure good outcomes. Of foremost importance is identifying and managing the source of ...

NANTES, France--(BUSINESS WIRE)--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase (ContraFect) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, ...

A novel imaging probe may make it possible to diagnose accurately a dangerous infection of the heart valves. Scientists have now shown how the presence of Staphylococcus aureus-associated endocarditis ...

CHF: Congestive heart failure; CI: Contraindication; DM: Diabetes mellitus; ICU: Intensive care unit; IE: Infective endocarditis; iv.: Intravenous; LV: Left ventricle ...

Endocarditis can be a life threatening complication of MRSA in which the infection causes inflammation in the lining of the heart, and its valves and chambers. Methicillin-resistant Staphylococcus ...

Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant ...